London, UK – 12 September 2025 – Avigen Ltd (“the Company”), a privately held Contract Research Organisation developing advanced preclinical immunotherapy R&D services using its proprietary microfluidic platform, today announced a preclinical research and development (R&D) collaboration with NK:IO, a biotechnology…